Abstract: Among 48 mutant isolates, 26 were B.1.1.7 (Alpha), 7 were E484K single mutation and the rest were other types of mutation.
Method: The initial checkpoint was set at nucleotide position nt23063 and if we found mutation from adenine (A) to thymine (T) at nt23063, further identification was done as follows: double mutation of A23063T (referred to N501Y) and C23271A (referred to A570D) for B.1.1.7 (Alpha), G23013A (referred to
Result: In April 2021, 65%, 29% and 6% were B.1.1.7 (Alpha), E484K mutations and other forms of mutation.
Result: In March 2021, 67% were B.1.1.7 (Alpha) and the rest were single E484K mutation.
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.
PMID: 35166573
2022
Science translational medicine
Introduction: Another VOC to emerge at about the same time was Beta (B.1.351), which is characterized by other NTD mutations and deletions, as well as crucial RBD mutations, including K417N, E484K, and N501Y.
Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies.
Result: In contrast, mutations in the Beta and Kappa S proteins, especially the E484K or E484Q substitution, may greatly impact RBM-targeting neutralizing MAbs.
Result: In fact, the RBM-targeting MAb 2H2 was greatly affected by the RBM mutations (K417N, E484K, and N501Y) in the Beta variant.
Result: Moreover, for 2H2, the other mutations, including K417N, E484K/Q, and N501Y mostly from the Beta and Kappa variants (N501Y also presented in the Alpha variant), all reside in its neutralizing epitopes on RBD.
Result: SARS-CoV-2 variants other than Delta harbor up to three distinct mutatio
Real-Time RT-PCR Allelic Discrimination Assay for Detection of N501Y Mutation in the Spike Protein of SARS-CoV-2 Associated with B.1.1.7 Variant of Concern.
Introduction: The E484K mutation has been observed in some B.1.1.7 genome sequences.
Introduction: This VOC has multiple mutations in the receptor-binding domain (RBD) of the S protein, including K417N, E484K, and N501Y.
Introduction: This VOC shares the S gene
Method: Clinical specimens that met these criteria with a CT value of <=30 underwent Sanger sequencing of a 698-bp (nucleotide positions 22516 to 23214) S gene fragment, which includes the locations of key receptor-binding domain (RBD) mutations (K417N/T, E484K, and N501Y).
Genomic Surveillance of SARS-CoV-2 Lineages Indicates Early Circulation of P.1 (Gamma) Variant of Concern in Southern Brazil.
Introduction: The P.1 lineage-defining mutations in the Spike protein, especially in the receptor-binding domains (RBD) such as K417T, E484K and N501Y, are of concern because they may enhance ACE2 affinity and contribute to antibody evasion.
Table: E484K
Discussion: According to our results, most of the P.1 sequences carried the 22 lineage-defining mutations, including the three mutations in the Spike protein, RBD domain (K417T, E484K and N501Y) associated with evasion of the immune system and greater transmissibility.
mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants.
Introduction: N501Y and two other mutations in the RBD domain, K417N/T and E484K, were subsequently founds in SARS-CoV-2 variants from South Africa (B.1.351) and Brazil (P.1).
Discussion: Other RBD mutations, K417N/T and E484K, either alone or in combinations, have not been evaluated in this study.
Characterization of the immune resistance of SARS-CoV-2 Mu variant and the robust immunity induced by Mu infection.
PMID: 35176774
2022
The Journal of infectious diseases
Abstract: Here we reveal that the two mutations in the SARS-CoV-2 Mu spike protein, YY144-145TSN and E484K, are responsible for the resistance to COVID-19 convalescent sera during early 2020 and vaccine sera.
Emergence in southern France of a new SARS-CoV-2 variant harbouring both N501Y and E484K substitutions in the spike protein.
Abstract: Fourteen of the amino acid substitutions, including N501Y and E484K, and nine deletions are located in the spike protein.
Introduction: In the receptor binding domain (RBD), in addition to the well-known substitutions N501Y and E484K, several changes were predicted to significantly affect the neutralizing epitopes.
Introduction: Subsequent detection of three mutations in the spike gene in a qPCR assay to screen for variants, as performed routinely in France in cases of SARS-CoV-2 positivity, revealed an atypical combination with L452R negativity, E484K positivity, and E484Q negativity (Pe
Immune transcriptome analysis of COVID-19 patients infected with SARS-CoV-2 variants carrying the E484K escape mutation identifies a distinct gene module.
Result: A direct comparison of RNA-seq data from patients infected with the Alpha or Alpha+E484K variant revealed the differential expression of 266 genes, with 122 being induced in the Alpha+E484K patients by at least two-fold.
Result: A total of 24 patients (18 Alpha patients and 6 Alpha+E484K patients) were homozygous for the OAS1 mutation (Supplementary Table 13).
Result: A total of 36 hospitalized patients infected with the Alpha variant and 13 patients infected with the Alpha+E484K variant participated in this study (for detailed information see Table 1 and Supplementary Table 1).
Result: BCs were isolated from the 36 hospitalized Alpha patients and 13 hospitalized Alpha+E484K patients and RNA-seq was conducted with an average of 215 mill
Table: E484K
The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals.
Discussion: Additionally, our data demonstrated that a lower antibody response was observed against the Beta variant, and not against the R.1 lineage variant, which indicates that the weak antibody response against the Beta variant was not solely due to the E484K mutation.
Discussion: Previous reports demonstrated that although the E484K mutation of Beta variants might cause humoral immunity escape, the combination of N501Y and K417N was further associated with a weakened response; this enhances the binding of the spike protein to ACE2 and reduces the binding to antibodies.
Discussion: Therefore, the E484K mutation of R.1 alone did not have a sufficient impact in reducing vaccine response, but the combination of E484K,
SARS_CoV_2 mutation literature information.
PMID: 
2022
Scientific reports
Browser Board
Co-occurred Entities
Filtrator
ViMRT